BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 31490007)

  • 1. A substantial proportion of apparently heterozygous TP53 pathogenic variants detected with a next-generation sequencing hereditary pan-cancer panel are acquired somatically.
    Coffee B; Cox HC; Bernhisel R; Manley S; Bowles K; Roa BB; Mancini-DiNardo D
    Hum Mutat; 2020 Jan; 41(1):203-211. PubMed ID: 31490007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apparently Heterozygous TP53 Pathogenic Variants May Be Blood Limited in Patients Undergoing Hereditary Cancer Panel Testing.
    Mester JL; Jackson SA; Postula K; Stettner A; Solomon S; Bissonnette J; Murphy PD; Klein RT; Hruska KS
    J Mol Diagn; 2020 Mar; 22(3):396-404. PubMed ID: 31881331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board.
    Xavier CB; Link R; Abreu L; Bettoni F; Marson F; Galante PAF; Masotti C; Amano MT; de Molla V; Camargo AA; Asprino PF; Sabbaga J
    Oncologist; 2023 Jul; 28(7):624-627. PubMed ID: 37159554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next generation sequencing is informing phenotype: a TP53 example.
    O'Shea R; Clarke R; Berkley E; Giffney C; Farrell M; O'Donovan E; Gallagher DJ
    Fam Cancer; 2018 Jan; 17(1):123-128. PubMed ID: 28509937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis.
    Batalini F; Peacock EG; Stobie L; Robertson A; Garber J; Weitzel JN; Tung NM
    Breast Cancer Res; 2019 Sep; 21(1):107. PubMed ID: 31533767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and Management of
    Pal T; Brzosowicz J; Valladares A; Wiesner GL; Laronga C
    South Med J; 2017 Oct; 110(10):643-648. PubMed ID: 28973705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
    Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
    J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and characteristics of likely-somatic variants in cancer susceptibility genes among individuals who had hereditary pan-cancer panel testing.
    Slavin TP; Coffee B; Bernhisel R; Logan J; Cox HC; Marcucci G; Weitzel J; Neuhausen SL; Mancini-DiNardo D
    Cancer Genet; 2019 Jun; 235-236():31-38. PubMed ID: 31056428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatic TP53 variants frequently confound germ-line testing results.
    Weitzel JN; Chao EC; Nehoray B; Van Tongeren LR; LaDuca H; Blazer KR; Slavin T; Facmg DABMD; Pesaran T; Rybak C; Solomon I; Niell-Swiller M; Dolinsky JS; Castillo D; Elliott A; Gau CL; Speare V; Jasperson K
    Genet Med; 2018 Aug; 20(8):809-816. PubMed ID: 29189820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical management of TP53 mosaic variants found on germline genetic testing.
    Ward A; Farengo-Clark D; McKenna DB; Safonov A; Good M; Le A; Kessler L; Shah PD; Bradbury AR; Domchek SM; Nathanson KL; Powers J; Maxwell KN
    Cancer Genet; 2024 Jun; 284-285():43-47. PubMed ID: 38677009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in TP53 Mutation Carrier Phenotypes Emerge From Panel-Based Testing.
    Rana HQ; Gelman R; LaDuca H; McFarland R; Dalton E; Thompson J; Speare V; Dolinsky JS; Chao EC; Garber JE
    J Natl Cancer Inst; 2018 Aug; 110(8):863-870. PubMed ID: 29529297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of
    Schwartz AN; Hyman SR; Stokes SM; Castillo D; Tung NM; Weitzel JN; Rana HQ; Garber JE
    JCO Precis Oncol; 2021 Nov; 5():1677-1686. PubMed ID: 34994652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1.
    Kumamoto T; Yamazaki F; Nakano Y; Tamura C; Tashiro S; Hattori H; Nakagawara A; Tsunematsu Y
    Int J Clin Oncol; 2021 Dec; 26(12):2161-2178. PubMed ID: 34633580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
    Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
    Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity.
    Penkert J; Schmidt G; Hofmann W; Schubert S; Schieck M; Auber B; Ripperger T; Hackmann K; Sturm M; Prokisch H; Hille-Betz U; Mark D; Illig T; Schlegelberger B; Steinemann D
    Breast Cancer Res; 2018 Aug; 20(1):87. PubMed ID: 30086788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome.
    Fortuno C; James PA; Spurdle AB
    Hum Mutat; 2018 Dec; 39(12):1764-1773. PubMed ID: 30240537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and molecular characterization of patients fulfilling Chompret criteria for Li-Fraumeni syndrome in Southern Brazil.
    Matzenbacher Bittar C; de Araújo Rocha YM; Vieira IA; Rosset C; Andreis TF; Sartor ITS; Artigalás O; Netto CBO; Alemar B; Macedo GS; Ashton-Prolla P
    PLoS One; 2021; 16(9):e0251639. PubMed ID: 34529667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer surveillance and distress among adult pathogenic TP53 germline variant carriers in Germany: A multicenter feasibility and acceptance survey.
    Rippinger N; Fischer C; Haun MW; Rhiem K; Grill S; Kiechle M; Cremer FW; Kast K; Nguyen HP; Ditsch N; Kratz CP; Vogel J; Speiser D; Hettmer S; Glimm H; Fröhling S; Jäger D; Seitz S; Hahne A; Maatouk I; Sutter C; Schmutzler RK; Dikow N; Schott S
    Cancer; 2020 Sep; 126(17):4032-4041. PubMed ID: 32557628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paired Tumor-Normal Sequencing Provides Insights Into the TP53-Related Cancer Spectrum in Patients With Li-Fraumeni Syndrome.
    Ceyhan-Birsoy O; Selenica P; Chui MH; Jayakumaran G; Ptashkin R; Misyura M; Aypar U; Jairam S; Yang C; Li Y; Mehta N; Kemel Y; Salo-Mullen E; Maio A; Sheehan M; Zehir A; Carlo M; Latham A; Stadler Z; Robson M; Offit K; Ladanyi M; Walsh M; Reis-Filho JS; Mandelker D
    J Natl Cancer Inst; 2021 Nov; 113(12):1751-1760. PubMed ID: 34240179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clonal Hematopoiesis and Mosaicism Revealed by a Multi-Tissue Analysis of Constitutional TP53 Status.
    Castillo D; Yuan TA; Nehoray B; Cervantes A; Tsang KK; Yang K; Sand SR; Mokhnatkin J; Herzog J; Slavin TP; Hyman S; Schwartz A; Ebert BL; Amos CI; Garber JE; Weitzel JN
    Cancer Epidemiol Biomarkers Prev; 2022 Aug; 31(8):1621-1629. PubMed ID: 35654360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.